Cargando…

Glucagon-like peptide-1 receptor overexpression in cancer and its impact on clinical applications

Peptide hormones of the glucagon-like peptide (GLP) family play an increasing clinical role, such as GLP-1 in diabetes therapy. Moreover, GLP receptors are overexpressed in various human tumor types and therefore represent molecular targets for important clinical applications. In particular, virtual...

Descripción completa

Detalles Bibliográficos
Autores principales:	Körner, Meike, Christ, Emanuel, Wild, Damian, Reubi, Jean Claude
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2012
Materias:	Endocrinology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3515855/ https://www.ncbi.nlm.nih.gov/pubmed/23230431 http://dx.doi.org/10.3389/fendo.2012.00158

Ejemplares similares

The Impact of Glucagon-Like Peptide-1 on Bone Metabolism and Its Possible Mechanisms
por: Zhao, Chenhe, et al.
Publicado: (2017)

Structural and Molecular Conservation of Glucagon-Like Peptide-1 and Its Receptor Confers Selective Ligand-Receptor Interaction
por: Moon, Mi Jin, et al.
Publicado: (2012)

Brunner's Gland Hyperplasia in a Patient after Roux-Y Gastric Bypass: An Important Pitfall in GLP-1 Receptor Imaging
por: Hepprich, Matthias, et al.
Publicado: (2020)

Preoperative Glucagon-like peptide-1 receptor imaging reduces surgical trauma and pancreatic tissue loss in insulinoma patients: a report of three cases
por: Wenning, Anna Silvia, et al.
Publicado: (2015)

The Interplay of Glucagon-Like Peptide-1 Receptor Trafficking and Signalling in Pancreatic Beta Cells
por: Marzook, Amaara, et al.
Publicado: (2021)

Dissecting the Physiology and Pathophysiology of Glucagon-Like Peptide-1
por: Paternoster, Silvano, et al.
Publicado: (2018)

GRK Inhibition Potentiates Glucagon-Like Peptide-1 Action
por: Lee, Seunghun P., et al.
Publicado: (2021)

A Glucagon-Like Peptide-1 Receptor Agonist Lowers Weight by Modulating the Structure of Gut Microbiota
por: Zhao, Li, et al.
Publicado: (2018)

It Is Time to Consider Glucagon-Like Peptide-1 Receptor Agonists for the Treatment of Type 2 Diabetes in Youth
por: Oberle, Megan M., et al.
Publicado: (2019)

Effect of dual glucose-dependent insulinotropic peptide/glucagon-like peptide-1 receptor agonist on weight loss in subjects with obesity
por: Zaffina, Isabella, et al.
Publicado: (2023)

Role of Glucagon and Its Receptor in the Pathogenesis of Diabetes
por: Jia, Yunbo, et al.
Publicado: (2022)

Overexpression of Gastrin-Releasing Peptide Receptors in Tumor-Associated Blood Vessels of Human Ovarian Neoplasms
por: Fleischmann, Achim, et al.
Publicado: (2007)

Utilization of glucagon-like peptide-1 receptor agonists in children and adolescents in China: a real-world study
por: Yan, Yilong, et al.
Publicado: (2023)

Ghrelin Is a Regulator of Glucagon-Like Peptide 1 Secretion and Transcription in Mice
por: Lindqvist, Andreas, et al.
Publicado: (2017)

Neurotensin receptors in pancreatic ductal carcinomas
por: Körner, Meike, et al.
Publicado: (2015)

CCK(2) receptor splice variant with intron 4 retention in human gastrointestinal and lung tumours
por: Körner, Meike, et al.
Publicado: (2010)

Impact of short and long exposure to cafeteria diet on food intake and white adipose tissue lipolysis mediated by glucagon-like peptide 1 receptor
por: Mattar, Pamela, et al.
Publicado: (2023)

Adult-onset nesidioblastosis: a challenging diagnosis revealed by glucagon-like-peptide-1 receptor imaging
por: Demartin, Sophie, et al.
Publicado: (2022)

A Combination of Glucagon-Like Peptide-1 Receptor Agonist and Dietary Intervention Could Be a Promising Approach for Obesity Treatment
por: Lee, Chooi Yeng
Publicado: (2021)

Decreased expression of Glucagon-like peptide-1 receptor and Sodium-glucose co-transporter 2 in patients with proliferative diabetic retinopathy
por: Chen, Hui, et al.
Publicado: (2022)

Corrigendum: Impact of short and long exposure to cafeteria diet on food intake and white adipose tissue lipolysis mediated by glucagon-like peptide 1 receptor
por: Mattar, Pamela, et al.
Publicado: (2023)

Glucagon-like peptide-2 protects the gastric mucosa via regulating blood flow and metabolites
por: Zhang, Jing, et al.
Publicado: (2022)

Glucagon-Like Peptide-1 Receptor Agonists for Non-Alcoholic Fatty Liver Disease in Type 2 Diabetes: A Meta-Analysis
por: Wong, Chloe, et al.
Publicado: (2021)

Computational Peptide Design Cotargeting Glucagon and Glucagon-like Peptide-1 Receptors
por: Vishnoi, Shubham, et al.
Publicado: (2023)

Comparison of the Efficacy of Glucagon-Like Peptide-1 Receptor Agonists in Patients With Metabolic Associated Fatty Liver Disease: Updated Systematic Review and Meta-Analysis
por: Dai, Yuzhao, et al.
Publicado: (2021)

Can glucagon-like peptide-1 receptor agonists cause acute kidney injury? An analytical study based on post-marketing approval pharmacovigilance data
por: Dong, Shichao, et al.
Publicado: (2022)

Comparison of the efficacy and safety of 10 glucagon-like peptide-1 receptor agonists as add-on to metformin in patients with type 2 diabetes: a systematic review
por: Xie, Zeyu, et al.
Publicado: (2023)

Glucagon Like Peptide 1 and MicroRNA in Metabolic Diseases: Focusing on GLP1 Action on miRNAs
por: Capuani, Barbara, et al.
Publicado: (2018)

Glucagon-Like Peptide 1 Receptor Agonists, Carotid Atherosclerosis, and Cardiovascular Outcomes
por: Marquis-Gravel, Guillaume, et al.
Publicado: (2021)

Real-world national trends and socio-economic factors preference of sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists in China
por: Li, Cao, et al.
Publicado: (2022)

Central Control of Feeding Behavior by the Secretin, PACAP, and Glucagon Family of Peptides
por: Sekar, Revathi, et al.
Publicado: (2017)

Impact of glucagon-like peptide 1 analogs on cognitive function among patients with type 2 diabetes mellitus: A systematic review and meta−analysis
por: Luan, Sisi, et al.
Publicado: (2022)

Crystal Structure of Glucagon-like Peptide-1 in Complex with the Extracellular Domain of the Glucagon-like Peptide-1 Receptor
por: Underwood, Christina Rye, et al.
Publicado: (2010)

Glucagon-like peptide-1 and glucagon-like peptide-1 receptor agonists in the treatment of type 2 diabetes
por: Lee, Seungah, et al.
Publicado: (2017)

Is Glucagon Receptor Activation the Thermogenic Solution for Treating Obesity?
por: Conceição-Furber, Ellen, et al.
Publicado: (2022)

RF32 | PSUN59 Glucagon-Like Peptide-1 Analogues: A New Way to Quit Smoking? SKIP – a Randomised Controlled Study
por: Atila, Cihan, et al.
Publicado: (2022)

Clinical and Physiological Characterization of Elevated Plasma Glucagon-Like Peptide-1 Levels (Hyperglipemia) in a Dipeptidyl Peptidase IV Mutation Carrier
por: Zhao, Dandan, et al.
Publicado: (2018)

Corrigendum: Central Control of Feeding Behavior by the Secretin, PACAP, and Glucagon Family of Peptides
por: Sekar, Revathi, et al.
Publicado: (2018)

Role of Glucagon-Like Peptide-1 Receptor Agonists in the Management of Non-Alcoholic Steatohepatitis: A Clinical Review Article
por: Ghazanfar, Haider, et al.
Publicado: (2021)

Self-assembled GLP-1/glucagon peptide nanofibrils prolong inhibition of food intake
por: Ouberai, Myriam M., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_ih65i0klmhln2ok305aq80gqpi